%0 Journal Article
%A 
%T Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience
%D 2026
%F 
%P 46-53
%V 10
%N 1
%R doi:10.14744/ejmi.263046
%U https://dx.doi.org/10.14744/ejmi.263046